Research programme: ISS-grass pollen conjugates - Dynavax

Drug Profile

Research programme: ISS-grass pollen conjugates - Dynavax

Alternative Names: ISS-grass pollen conjugates research programme - Dynavax

Latest Information Update: 06 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 22 Mar 2005 Dynavax's ISS-grass pollen conjugates programme is no longer licensed to UCB worldwide
  • 24 Oct 2003 Preclinical trials in Seasonal allergic rhinitis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top